NKTR
$21.63
Nektar Therapeutics
($.07)
(.32%)
NKTR
Earnings Whisper ®
N/A
2nd Quarter June 2020
Consensus:  ($0.69)
Revenue:  $22.85 Mil
Thursday
Aug 6
4:15 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when NKTR reports earnings?
Beat
Meet
Miss

Where is NKTR's stock price going from here?
Up
Flat
Down
Stock chart of NKTR
Analysts
Summary of analysts' recommendations for NKTR
Score
Grade
Pivots
Resistance
$23.53
$22.91
$22.31

$21.69

Support
$21.09
$20.47
$19.87
Tweet
Growth
Description
Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain. In the area of pain, Nektar has a worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation. The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid. Also in the area of pain, NKTR-181, the company's wholly-owned novel mu-opioid analgesic molecule, is being evaluated in Phase 1 clinical studies. Nektar Therapeutics is headquartered in San Francisco, California.
Peers
Regeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalJohnson & JohnsonInterCeptZoetisMylanBristol-Myers SquibbUltragenyx PharmaceuticalEndo International plc